The Scottish Medicines Consortium (SMC) has rejected Daiichi Sankyo’s new cholesterol-lowering drug Nilemdo for use by NHS Scotland, saying the evidence backing the drug isn’t strong enough.
Over the years, the Company has carved a niche as one of the leading speciality chemical manufacturers in India. The product range of the Company has grown in line with the changing needs of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback